Current Report Filing (8-k)
June 19 2020 - 8:51AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 15, 2020
HOOKIPA PHARMA INC.
(Exact name of Registrant as Specified in
Its Charter)
Delaware
|
|
001-38869
|
|
81-5395687
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
350 Fifth Avenue, 72nd Floor, Suite
7240
|
|
|
New York, New York
|
|
10118
|
(Address of principal executive offices)
|
|
(zip code)
|
Registrant’s telephone number, including
area code: +43 1 890 63 60
Not Applicable
Former name or former address, if changed
since last report
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instructions A.2. below):
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common stock, $0.0001 par value per
share
|
|
HOOK
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. x
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Resignation of Sander van Deventer
On June 15, 2020, Sander van Deventer, M.D., Ph.D. notified
HOOKIPA Pharma Inc. (the “Company”) of his intent to resign from the Company’s Board of Directors (the “Board”)
and from his position as member of the Audit Committee of the Board, effective as of June 16, 2020. Dr. van Deventer’s decision
to resign from the Board was not the result of any dispute or disagreement with the Company or the Company’s Board on any
matter relating to the operations, policies or practices of the Company.
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
The Company held its previously announced Annual Meeting of
Stockholders (the “Annual Meeting”) on June 18, 2020, at which a quorum was present. As of April 20, 2020,
the record date for the Annual Meeting, there were 21,824,990 shares of the Company’s common stock outstanding and entitled
to vote at the Annual Meeting. The Company’s stockholders voted on the following matters, which are described in detail in
the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 28, 2020: (i)
to elect Joern Aldag, Jan van de Winkel and David R. Kaufman as Class I directors of the Company each to serve for a three-year
term expiring at the Company’s annual meeting of stockholders in 2023 and until their successors have been elected and qualified
(“Proposal 1”) and (ii) to ratify the appointment of PwC Wirtschaftsprüfung GmbH as the Company’s
independent registered public accounting firm for the fiscal year ending December 31, 2020 (“Proposal 2”).
The Company’s stockholders approved the Class I director
nominees recommended for election in Proposal 1 at the Annual Meeting. The Company’s stockholders voted for the Class I
directors as follows:
Class I Director Nominee
|
|
For
|
|
|
Withhold
|
|
|
Broker Non-Votes
|
|
Joern Aldag
|
|
|
13,126,298
|
|
|
|
222,396
|
|
|
|
2,831,834
|
|
Jan van de Winkel
|
|
|
11,023,253
|
|
|
|
2,325,441
|
|
|
|
2,831,834
|
|
David R. Kaufman
|
|
|
13,121,422
|
|
|
|
227,272
|
|
|
|
2,831,834
|
|
The Company’s stockholders approved Proposal 2. The votes
cast at the Annual Meeting were as follows:
For
|
|
Against
|
|
Abstain
|
16,145,049
|
|
25,295
|
|
10,184
|
No other matters were submitted to or voted on by the Company’s
stockholders at the Annual Meeting.
On June 19, 2020, the Company issued a press release announcing
the resignation of Sander van Deventer as a member of the Board. A copy of the press release is attached as Exhibit 99.1 to this
report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 19, 2020
|
HOOKIPA Pharma Inc.
|
|
|
|
|
By:
|
/s/ Joern Aldag
|
|
|
Joern Aldag
Chief Executive Officer
(Principal Executive Officer)
|
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Aug 2024 to Sep 2024
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Sep 2023 to Sep 2024